Novartis (NVS) said Thursday the US Food and Drug Administration has approved Fabhalta to treat adults with C3 glomerulopathy, the first therapy cleared for the condition.
The oral drug is designed to reduce protein in urine and targets a part of the immune system thought to drive the disease, the company said.
Data from a phase 3 trial showed a sustained drop in protein levels over one year, with no unexpected safety issues reported.
C3G is an uncommon kidney disorder usually diagnosed in young adults and often ends in kidney failure within a decade, according to Novartis.
The company said the treatment is also being reviewed in other regions, including Europe, China, and Japan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.